Maarten R Grootendorst1,2, Massimiliano Cariati1,2, Sarah E Pinder1, Ashutosh Kothari2, Michael Douek1,2, Tibor Kovacs2, Hisham Hamed2, Amit Pawa3, Fiona Nimmo4, Julie Owen1, Vernie Ramalingam2, Sweta Sethi2, Sanjay Mistry2, Kunal Vyas5, David S Tuch6, Alan Britten7, Mieke Van Hemelrijck1, Gary J Cook8, Chris Sibley-Allen9, Sarah Allen9, Arnie Purushotham10,2. 1. Division of Cancer Studies, King's College London, London, United Kingdom. 2. Department of Breast Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 3. Anesthetic Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 4. Day Surgery Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 5. Sagentia Ltd., Cambridge, United Kingdom. 6. Lightpoint Medical Ltd., Chesham, United Kingdom. 7. Medical Physics Department, St George's Hospital, London, United Kingdom. 8. Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom; and. 9. Department of Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 10. Division of Cancer Studies, King's College London, London, United Kingdom arniepurushotham@gmail.com.
Abstract
In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the γ-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 ± 15 μSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.
In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the γ-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 ± 15 μSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.
Authors: Nikunj B Bhatt; Darpan N Pandya; William A Dezarn; Frank C Marini; Dawen Zhao; William H Gmeiner; Pierre L Triozzi; Thaddeus J Wadas Journal: Methods Mol Biol Date: 2018
Authors: Wes M Allen; Ken Y Foo; Renate Zilkens; Kelsey M Kennedy; Qi Fang; Lixin Chin; Benjamin F Dessauvagie; Bruce Latham; Christobel M Saunders; Brendan F Kennedy Journal: Biomed Opt Express Date: 2018-11-19 Impact factor: 3.732
Authors: Israt S Alam; Idan Steinberg; Ophir Vermesh; Nynke S van den Berg; Eben L Rosenthal; Gooitzen M van Dam; Vasilis Ntziachristos; Sanjiv S Gambhir; Sophie Hernot; Stephan Rogalla Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Suman B Mondal; Christine M O'Brien; Kevin Bishop; Ryan C Fields; Julie A Margenthaler; Samuel Achilefu Journal: J Nucl Med Date: 2020-04-17 Impact factor: 10.057
Authors: Christopher Darr; Nina N Harke; Jan Philipp Radtke; Leubet Yirga; Claudia Kesch; Maarten R Grootendorst; Wolfgang P Fendler; Pedro Fragoso Costa; Christoph Rischpler; Christine Praus; Johannes Haubold; Henning Reis; Thomas Hager; Ken Herrmann; Ina Binse; Boris Hadaschik Journal: J Nucl Med Date: 2020-02-14 Impact factor: 10.057
Authors: Benjamin W Maloney; David M McClatchy; Brian W Pogue; Keith D Paulsen; Wendy A Wells; Richard J Barth Journal: J Biomed Opt Date: 2018-10 Impact factor: 3.170
Authors: Rebecca W Gao; Nutte T Teraphongphom; Nynke S van den Berg; Brock A Martin; Nicholas J Oberhelman; Vasu Divi; Michael J Kaplan; Steven S Hong; Guolan Lu; Robert Ertsey; Willemieke S F J Tummers; Adam J Gomez; F Christopher Holsinger; Christina S Kong; Alexander D Colevas; Jason M Warram; Eben L Rosenthal Journal: Cancer Res Date: 2018-07-02 Impact factor: 12.701